Mycetohabitans rhizoxinica (previously Burkholderia rhizoxinica) and M. endofungorum are endofungal bacteria inhabiting Rhizopus microsporus mold. These bacteria form symbiosis to help the mold infect plants and produce mycotoxins, such as rhizoxin, that cause rice seedling blight (1, 2). Genetically, Mycetohabitans species are highly similar to Burkholderia species but with significantly smaller genome sizes (3.3–3.8 Mb vs. 5.8–11 Mb), reflecting their endosymbiotic nature (3). R. microsporus causes mucormycosis, a devastating invasive fungal infection seen most prevalently in immunocompromised patients, but no strong evidence has suggested that the symbiont bacteria contribute to the pathogenicity of R. microsporus mold in humans (1, 4). Isolation of endofungal bacteria have seldom been reported in clinical settings, most likely because of limitations in identification methods. In a study performed by the Centers for Disease Control and Prevention, M. rhizoxinica and M. endofungorum isolated from blood and wounds were characterized as oxidase-positive, gram-negative coccobacilli and could be reliably identified only by sequencing; no clinical information was provided to characterize the clinical presentation nor did researchers describe any link to R. microsporus (4). We report M. rhizoxinica bacteremia associated with multifocal pneumonia presumptively caused by R. microsporus mold in a severely immunocompromised patient.

**The Study**

A 65-year-old woman in California, USA, with a history of relapsed and refractory multiple myeloma visited a hospital to receive chimeric antigen receptor T-cell therapy. She previously had received 3 doses of the COVID-19 mRNA vaccine. On the day after CAR T-cell therapy, she experienced a rapid decline in mental status, accompanied by fever and hypotension, and was transferred to the intensive care unit. At that time, her total leukocyte count was 0.09 × 10^3 cells/μL. Nasopharyngeal testing for COVID-19 by PCR was negative. She was diagnosed with immune effector cell-associated neurotoxicity syndrome and cytokine release syndrome. She received high doses of dexamethasone and 4 doses of tocilizumab, as well as anakinra, which was tapered over 7 days. The patient’s symptoms improved, and she was discharged after a 15-day hospital stay, with plans for a prolonged taper of orally administered dexamethasone (8 mg 2×/d). On discharge, the patient’s leukocyte count was 1.4 × 10^3 cells/μL (87% neutrophils, 7% lymphocytes); the next day, her outpatient blood work showed mild lactic acidosis.

Four days after leaving the hospital, the patient sought treatment at an outpatient oncology clinic, reporting generalized weakness and fatigue. We performed blood and urine analyses and began a regimen of oral levofloxacin (500 mg daily). On day 6 after discharge, we noted a positive blood culture result, with a gram-negative rod. The urine culture grew 30,000 CFU/mL of Klebsiella pneumoniae. When evaluating the patient during clinical rounds, we...
performed repeat blood and urine cultures and recommended inpatient management, which was refused. We administered 1 intravenous dose of meropenem (1 g) at that visit and 1 dose of intravenous ceftriaxone (2 g) the next day.

On day 8 after discharge, the patient sought emergency treatment for worsening foot and ankle pain. Her leukocyte count was $0.44 \times 10^3$ cells/µL. Bacterial identification of the positive blood culture was still pending. Results of repeat blood and urine cultures and COVID-19 PCR testing (nasopharyngeal) were negative; chest radiograph showed right-, middle-, and lower-lobe airspace opacification (Figure 1, panel A). We began piperacillin/tazobactam and performed an arthrocentesis, which showed crystals but revealed a negative Gram stain. Shortly thereafter, the patient reported acute numbness and weakness of her right leg. She subsequently developed dyspnea, respiratory distress, and altered mental status. We intubated her and conducted magnetic resonance imaging, which showed an acute infarct of the left medial parietal lobe, with hemorrhagic transformation (Figure 1, panel B). We transferred the patient to the intensive care unit, where she was febrile ($38.2^\circ$C) and required 2 vasoressors. We administered vancomycin, caspofungin, and isavuconazole. The next day, hypotension worsened, requiring 3 vasoressors. Leukocyte was $0.16 \times 10^3$ cells/µL. On hospital day 3, we obtained a tracheal aspirate for cultural analysis. Later that day, pulseless electrical activity occurred; the patient suffered cardiac arrest and died.

The day after her death, results of analysis of tracheal aspirate obtained on hospital day 3 revealed a mold. The bacteria from the initial positive blood culture were gram-negative, oxidase-positive cocobacilli not identifiable by the Vitek MS system (bioMérieux, https://www.biomerieux.com). The specimen was automatically reflected to a laboratory-developed whole-genome sequencing (WGS) identification test.

![Figure 1. Imaging studies from a 65-year-old woman with multiple myeloma undergoing chimeric antigen receptor T-cell therapy who was admitted to the hospital for worsening foot and ankle pain, California, USA. A) Chest radiograph image, showing a moderate right-sided pleural effusion and adjacent pulmonary opacities indicative of pneumonia. B) Magnetic resonance imaging of the patient’s brain, showing the infarct involving the left medial parietal lobe.](image)

| Antibiotic                        | MIC, µg/mL* |
|-----------------------------------|-------------|
| Amoxicillin/clavulanate           | $\leq 2$    |
| Ceftriaxone                       | $\leq 1$    |
| Ceftazidime                       | $\leq 0.5$  |
| Ceftolozane/tazobactam           | $\leq 0.5$  |
| Cefepime                          | $\leq 0.5$  |
| Ceftazidime/avibactam            | $\leq 2$    |
| Ertapenem                         | $\leq 0.25$ |
| Imipenem                          | $\leq 1$    |
| Meropenem                         | $\leq 0.25$ |
| Piperacillin/tazobactam           | $\leq 8$    |
| Amikacin                          | 8           |
| Gentamicin                        | $\leq 1$    |
| Tobramycin                        | $\leq 1$    |
| Ciprofloxacin                     | 0.5         |
| Levofloxacin                      | $\leq 0.5$  |
| Trimethoprim/sulfamethoxazole     | $\leq 1/20$ |

*Susceptibility testing was performed on broth-microdilution panels prepared in-house in accordance with CLSI guidelines from the Clinical and Laboratory Standards Institute (https://www.clsi.org).
Drug-susceptibility testing showed presumptive (due to lack of breakpoint) susceptibility to most drugs tested, including amoxicillin/clavulanate, ceftriaxone, piperacillin/tazobactam, carbapenems, gentamicin, ciprofloxacin, and trimethoprim/sulfamethoxazole (Table).

We performed WGS on the bacteria from both the blood and the mold obtained from tracheal suction using Illumina MiSeq (Illumina, https://www.illumina.com) (5) (Figure 2). We identified the bacteria as *Mycetohabitans rhizoxinica*, with >99% identity in all 3 full-length marker genes compared with the type strain *M. rhizoxinica* HKI 454 (GenBank accession no. NC_014722.1). We identified the mold as *Rhizopus microsporus* var. chinensis CBS 631.82 (accession no. NR_149337.1 for ITS and HM849668.1 for D1–D2) (Table).

We mapped the whole genome sequences of the bacteria and mold isolates (Genbank Sequence Read Archive data: PRJNA857096) to the *M. rhizoxinica* HKI 454 complete genome sequence (5). Figure 2. Whole-genome sequencing analysis of bacterial and fungal isolates (A) in a 65-year-old woman with multiple myeloma undergoing chimeric antigen receptor T-cell therapy, California, USA. The bacteria were identified as *Mycetohabitans rhizoxinica* with >99% identity in all 3 full-length marker genes compared with the reference organism (B, left side). The mold was identified as *Rhizopus microsporus* with >99% identity in the ITS gene and the D1–D2 region of the 28S gene compared with a reference organism (B, right side). Whole-genome sequences of the bacteria from blood (C, left side) revealed whole-genome coverage 94.0% and pairwise identity 95.5% with sufficient mean coverage of 298x. Whole-genome sequence of the mold from tracheal aspirate (C, right side) aligned to reference bacterial whole-genome sequence showed whole-genome coverage 94.1% and pairwise identity 95.8%, with sufficient mean coverage of 75x. The bacteria inside the mold from the trachea were genetically identical to the bacteria from the blood, as shown by the SNP analysis (D). ITS, internal transcribed spacer; SNP, single nucleotide polymorphism.
Using WGS, we present clear evidence linking the endofungal bacteria *M. rhizoxinica*, isolated from a patient’s blood, to the bacteria residing within the *R. microsporus* mold isolated from the patient’s respiratory sample. The bacteria were isolated in the blood culture before initiating antibiotics were pansusceptible to the antibiotics tested, and cleared quickly after treatment. However, it is not clear whether the antibiotics retained activity against the bacteria within the fungal cytoplasm or whether activity was preserved for only bacteria outside the fungi. We hypothesize that the bacteria were most likely inside the mold in vivo and freed only after sample collection and then grew in the blood culture bottle during the incubation, when the fungus became degraded or lysed. Blood culture has low yield for mucorales species (8), indicating those molds often die during the blood culture process. Because of the clinical manifestation, we believe the bacteria did not contribute to sepsis but rather served as a signal for a developing invasive mold infection that manifested during the immune suppression related to the patient’s CAR T-cell therapy. Unfortunately, the patient decompensated rapidly and died before the mold was identified and before we could initiate aggressive antifungal treatment.

Infarction and necrosis of infected tissues are hallmarks of mucormycosis (9). Disseminated mucormycosis, the presumptive diagnosis in this case based on the pulmonary findings and hemorrhagic brain infarction, is a rapidly progressive infection associated with a mortality rate >90% (10). This patient was at risk for disseminated mucormycosis because of profound immune suppression. Early diagnosis and prompt treatment of mucormycosis are key to improving clinical outcomes. Disseminated mucormycosis appears to be the underlying infectious process in this case, but this report lacks autopsy examination to confirm the presumptive diagnosis.

In conclusion, we found that isolation of endofungal bacteria *M. rhizoxinica* in the clinical setting might indicate invasive *Rhizopus* infection. Because identification methods used in most clinical laboratories are limited, endofungal bacteria may be underrecognized and require sequencing to identify.

**Acknowledgement**

We thank the University of California–Los Angeles Clinical Microbiology Laboratory for technical support.

This work was supported by the National Institutes of Health (K01TW012170 to PCA).

### References

1. Frey-Klett P, Burlinson P, Deveau A, Barrett M, Tarkka M, Sarmiguet A. Bacterial-fungal interactions: hyphens between agricultural, clinical, environmental, and food microbiologists. Microbiol Mol Biol Rev. 2011;75:583–609. https://doi.org/10.1128/MMBR.00206-11
2. Lackner G, Hertweck C. Impact of endofungal bacteria on infection biology, food safety, and drug development. PLoS Pathog. 2011;7:e1002096. https://doi.org/10.1371/journal.ppat.1002096
3. Estrada-de los Santos P, Palmer M, Chávez-Ramírez B, Beukes C, Steenkamp ET, Briscoe L, et al. Whole genome analyses suggests that *Burkholderia sensu lato* contains two additional novel genera (*Mycetohabitans* gen. nov., and *Trinickia* gen. nov.): implications for the evolution of diazotrophy and nodulation in the *Burkholderiaceae*. Genes (Basel). 2018;9:389. https://doi.org/10.3390/genes9080389
4. Gee JE, Glass MB, Lackner G, Helsel LO, Daneshvar M, Hollis DG, et al. Characterization of *Burkholderia rhizoxinica* and *B. endofungorum* isolated from clinical specimens. PLoS One. 2011;6:e15731. https://doi.org/10.1371/journal.pone.0015731
5. Price TK, Relegeno S, Mirsalis R, Tsan A, Chandrasekaran S, Garner OB, et al. Validation, implementation, and clinical utility of whole genome sequence-based bacterial identification in the clinical microbiology laboratory. J Mol Diagn. 2021;23:1468–77. https://doi.org/10.1016/j.jmoldx.2021.07.020
6. Price TK, Mirsalis R, Ward KW, Dayo AJ, Hilt EE, Chandrasekaran S, et al. Genomic characterizations of clade
7. Partida-Martinez LP, Hertweck C. A gene cluster encoding rhizoxin biosynthesis in “Burkholderia rhizoxina”, the bacterial endosymbiont of the fungus Rhizopus microsporus. ChemBioChem. 2007;8:41–5. https://doi.org/10.1002/cbич.200600393

8. Walsh TJ, Gamaletou MN, Maginnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54 (Suppl 1):S55–60. https://doi.org/10.1093/cid/cir868

9. Petrikkos G, Skiada A, Lortholy O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54 (Suppl 1):S23–34. https://doi.org/10.1093/cid/cir866

10. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaeufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53. https://doi.org/10.1086/432579

Address for correspondence: Shangxin Yang, UCLA Clinical Microbiology Laboratory, 11633 San Vicente Blvd, Los Angeles, CA 90049, USA; email: shangxinyang@mednet.ucla.edu